using the Five-Factor Score to guide therapy. The Five-Factor Score (FFS), first published in 1996 Ungraded position statement: In patients with sinonasal involvement in EGPA, treatment with nasal rinses and topical therapies (e.g., antibiotics, lubricants, and glucocorticoids) may be considered. Allergic rhinitis and sinonasal disease are frequent clinical features of EGPA. Although the efficacy of nasal rinses and topical | 1103 therapies in EGPA is not well established, some patients may benefit. Where possible, consultation with an otolaryngologist with expertise in treating AAV should be obtained to guide the use and choice of these agents. These interventions can continue to be beneficial even when symptoms have improved or resolved. Recommendation: For patients with EGPA who are receiving cyclophosphamide or rituximab, we conditionally recommend prescribing medications for prophylaxis to prevent P jirovecii pneumonia. Prophylaxis to prevent P jirovecii pneumonia is discussed